Intellia Therape Stock Price, News & Analysis

Intellia Therapeutics (NASDAQ:NTLA) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical programs. The company has initiated dosing in the global Phase 3 HAELO study for NTLA-2002 in hereditary angioedema (HAE), with enrollment completion expected in H2 2025 and BLA submission planned for H2 2026.

The Phase 3 MAGNITUDE trial for nexiguran ziclumeran (nex-z) in ATTR amyloidosis is advancing ahead of schedule, targeting over 550 patients by year-end. The company maintains a strong financial position with $861.7 million in cash and equivalents as of December 31, 2024, expected to fund operations into H1 2027.

Q4 2024 financial results show collaboration revenue of $12.9 million, R&D expenses of $116.9 million, and G&A expenses of $32.4 million. The company reported a net loss of $128.9 million. In January 2025, Intellia announced a strategic restructuring, reducing workforce by 27% to focus on late-stage programs.

Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has announced it will host a conference call on February 27, 2025, at 8 a.m. ET to discuss its fourth quarter and full-year 2024 financial results and operational highlights.

U.S. participants can dial 1-833-316-0545, while international callers should use 1-412-317-5726. A live webcast will be available, and a replay will be accessible through the company's website starting at 12 p.m. ET on the same day.

Intellia Therapeutics (NASDAQ:NTLA) has announced the award of inducement grants to three new employees under its 2024 Inducement Plan. The grants consist of time-based restricted stock units (RSUs) for 21,863 shares of common stock, which will vest in three equal installments on February 1 of 2026, 2027, and 2028. The vesting is contingent upon continued service with Intellia.

The awards were granted outside of Intellia's stockholder-approved equity incentive plans through the 2024 Inducement Plan, which was adopted by the board in June 2024. The compensation committee approved these grants as material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Intellia Therapeutics (NASDAQ:NTLA) has announced the dosing of the first patient in its global Phase 3 HAELO study of NTLA-2002, an investigational in vivo CRISPR gene editing treatment for hereditary angioedema (HAE). The company expects to complete enrollment in the second half of 2025 and submit a biologics license application (BLA) in 2026, aiming for a U.S. launch in 2027.

NTLA-2002 is being developed as a single-dose treatment for this potentially life-threatening disease. The company plans to present longer-term data from the ongoing Phase 1/2 study later this year to demonstrate the treatment's durability of effect.

Intellia Therapeutics (NASDAQ:NTLA) announced strategic reorganization and 2025 milestones, focusing on two priority programs: NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for ATTR amyloidosis. The company plans to complete enrollment for the Phase 3 HAELO study in H2 2025 and aims to submit a Biologics License Application in H2 2026.

The reorganization includes discontinuing NTLA-3001 development and implementing a 27% workforce reduction in 2025, resulting in approximately $8 million in charges. With approximately $862 million in cash and investments at Q4 2024, combined with cost savings, the company expects to maintain operations into H1 2027.

Key 2025 objectives include enrolling over 550 patients in the MAGNITUDE study for nex-z, completing commercial leadership team buildout, and advancing medical education initiatives. The company also announced leadership changes, with CSO Laura Sepp-Lorenzino retiring and Birgit Schultes promoted to Executive VP and CSO.

Intellia Therapeutics (NASDAQ:NTLA) has granted inducement awards to three new employees under its 2024 Inducement Plan. The grants consist of time-based restricted stock units (RSUs) for 23,155 shares of common stock, which will vest in three equal installments on January 1 of 2026, 2027, and 2028. The vesting is contingent upon continued employment with Intellia.

These awards were granted outside of Intellia's stockholder-approved equity incentive plans through the 2024 Inducement Plan, which was adopted by the board in June 2024. The compensation committee approved these grants as material inducement for employment in compliance with Nasdaq Listing Rule 5635(c)(4).

Intellia Therapeutics (NASDAQ:NTLA) has announced an inducement grant award to a new employee under its 2024 Inducement Plan. The grant consists of 3,521 restricted stock units (RSUs) of Intellia's common stock, which will vest in three equal installments on December 1 of 2025, 2026, and 2027. The award was granted outside of Intellia's stockholder-approved equity incentive plans and was approved by the company's compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Intellia Therapeutics (NASDAQ:NTLA) announced that its investigational therapy nexiguran ziclumeran (nex-z) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for treating hereditary transthyretin amyloidosis with polyneuropathy. This single-dose CRISPR-based treatment aims to inactivate the TTR gene to prevent TTR protein production. The designation was granted based on promising Phase 1 data showing rapid, deep, and durable TTR reduction. This marks the third special regulatory designation for nex-z, following Orphan Drug Designations from both the FDA and European Commission.

Intellia Therapeutics announced positive clinical data from its ongoing Phase 1 trial of nexiguran ziclumeran (nex-z), a CRISPR-based gene editing therapy for ATTR amyloidosis. The one-time treatment showed consistently rapid, deep, and durable reduction in serum TTR, with evidence of disease stabilization or improvement. In the ATTR-CM arm, patients demonstrated favorable trends across cardiac disease markers at month 12, with a mean 90% serum TTR reduction. The ATTRv-PN arm showed similar positive trends with 91% TTR reduction at month 12. The therapy maintained a favorable safety profile, with mainly mild to moderate infusion-related reactions reported.